Echelon Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

echelon-inc.com

Stage

Loan | Alive

Total Raised

$400K

Last Raised

$250K | 2 yrs ago

About Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Echelon Biosciences Headquarter Location

675 Arapeen Dr Suite 302 Suite 32

Salt Lake City, Utah, 84108,

United States

801-588-0455

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Echelon Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Echelon Biosciences is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Echelon Biosciences Patents

Echelon Biosciences has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/12/2010

8/20/2013

Molecular biology, Vegetable oils, Biotechnology, Metabolism, Enzymes

Grant

Application Date

5/12/2010

Grant Date

8/20/2013

Title

Related Topics

Molecular biology, Vegetable oils, Biotechnology, Metabolism, Enzymes

Status

Grant

Latest Echelon Biosciences News

HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools

Apr 14, 2021

Download HTL's campus is located in Paris, France. HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products. https://htlbiotech.com/ HTL's campus is located in Paris, France. HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products. https://htlbiotech.com/ Echelon Biosciences Inc'.s campus is located in Salt Lake City, Utah. HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products. https://echelon-inc.com/echelon-htl-partnership/ April 14, 2021 06:00 AM Eastern Daylight Time SALT LAKE CITY & PARIS--( BUSINESS WIRE )-- HTL , the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc. , a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products. The partnership provides academic research and pharmaceutical development laboratories’ expanded access to Good Manufacturing Practices (GMP)-grade, kit-packaged hyaluronic acid and glycosaminoglycan (GAG) products. By offering premium, clinical grade products to early-stage research investigators, the partnership seeks to bridge the gap between lab-based research, development and commercialization, and accelerate innovation worldwide. “Innovation is at the heart of HTL’s DNA,” said HTL CEO Yvon Bastard . “This growth opportunity reinforces our mission and vision to apply science for increased bio-compatibility and improved health outcomes around the world.” “This new partnership offers scientists and researchers the key technologies to develop innovative biopolymer solutions for new medical applications in aesthetics, ophthalmology, rheumatology, tissue engineering and drug delivery,” said Charles Ruban , HTL deputy CEO. “This is the true meaning of HTL’s tagline of ‘Beyond, together.’ HTL’s ambition is not only to grow its lead position in producing and distributing hyaluronic acid worldwide, but also to build tomorrow’s glycosaminoglycan-based solutions.” “Echelon has been granted the opportunity to expand its market-leading HA assays and extra cellular matrix product line with the supply of HTL ’s hyaluronic acid and other GAG-derived products. HTL is recognized internationally for producing biopolymers of premium quality,” says Bert Israelsen , president of Echelon Biosciences . “Echelon offers our customers access to the latest innovative tools with unparalleled technical support, thereby fully enabling maximized creativity in basic and applied research. With its fermentation and organic synthesis platforms, HTL creates functionality and added value by developing chemically modified biopolymers tailored to specific needs.” “This new partnership is a milestone in HTL’s expanding footprint in the North American market and with the U.S. medical community,” said Glenn Prestwich, Ph.D ., one of Echelon’s founders and now HTL’s exclusive science and innovation advisor for this market. By entrusting Echelon with the distribution of HTL’s hyaluronic acid and glycosaminoglycan products for research use, HTL aims to significantly increase its support and involvement in biopolymer research in the U.S. and worldwide, but also its research and development capacity. “This new initiative demonstrates HTL’s commitment to invest in innovation in healthcare,” said Humberto C. Antunes , strategic advisor to HTL and former CEO of Galderma. “In the fields of health and wellness, the biotechnology ecosystem of innovation, incubators, and established and emerging companies are incredibly dynamic in the United States, Mexico and Canada. It means a huge growth potential for HTL products,” added Antunes. About HTL HTL is a biotechnology company, leading the way in the design and production of pharmaceutical grade hyaluronic acid and other innovative functional biopolymers for premium medical products. HTL serves the pharmaceutical and medical device industries worldwide, enabling them to transform lives of patients. HTL’s unsurpassed commitment to client partnership has been consistently proven in the marketplace. The company is recognized for supplying the highest quality products and continually investing in driving and supporting market growth. For over 25 years, its cutting-edge research and development has allowed to develop unique value-driven solutions to meet the innovation needs of its clients. About Echelon Biosciences, Inc. Based in Salt Lake City, Utah, Echelon Biosciences, was established in 1997 to supply synthetic lipid reagents for research and development. Since then, Echelon has successfully grown in scale and scope to include custom chemistry, peptides, and biological assays with over 700 catalog items in the fields of cell signaling, extracellular matrix, cancer drug discovery, and disease biomarkers.

Echelon Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Echelon Biosciences Rank

  • Where is Echelon Biosciences's headquarters?

    Echelon Biosciences's headquarters is located at 675 Arapeen Dr Suite 302, Salt Lake City.

  • What is Echelon Biosciences's latest funding round?

    Echelon Biosciences's latest funding round is Loan.

  • How much did Echelon Biosciences raise?

    Echelon Biosciences raised a total of $400K.

  • Who are the investors of Echelon Biosciences?

    Investors of Echelon Biosciences include Paycheck Protection Program and National Science Foundation.

  • Who are Echelon Biosciences's competitors?

    Competitors of Echelon Biosciences include Cognition Therapeutics, Carmot Therapeutics, Lycera, Melior Discovery, SciTech Development, Phylogeny, Ensol Biosciences, Sword Diagnostics, Creabilis Therapeutics, Floragenex and 45 more.

You May Also Like

A
Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

V
VivoPath

VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

DiscoveryBioMed Logo
DiscoveryBioMed

DiscoveryBioMed (DBM) is a life sciences and biotechnology company. DiscoveryBioMed's mission is to fill a critical niche within the drug discovery industry by specializing in custom human cell engineering and human cell-based drug discovery. Its R&D infrastructure and know-how are leveraged as a CRO service to support the commercial and academic drug discovery community by integrating human cell platforms at any and all points within the drug discovery critical path, from HTS assay development and optimization to lead prioritization and progression, with the end product being 'high value' clinical candidates.

A
Alzeim

Alzheimer's Disease is a modern curse that negates the many benefits from modern medicine and improved standards of hygiene and living. As the human population life-span is increased, a larger percentage of people will succumb to debilitating and distressing memory loss. Alzeim is dedicated to making available a natural plant alkaloid " Galanthamine (also widely called Galantamine) - that is proven to be a drug in the alleviation of memory-loss symptoms.nIt has few adverse side-effects and is currently extremely expensive to produce either from wild plants or by synthesis. By the application of research adding to its existing framework of knowledge, the company is establishing a new agri-industry in an upland region of Wales. Once production is adequate, it will make Galanthamine more widely available and affordable. Daffodils grown in the Black Mountains - helping Alzheimer's patientsnnGalanthamine has been known for some time as one of the few effective treatments for patients at certain stages of Alzheimer's Disease, having been produced in its natural form from plants found in the wild " principally in the Balkan region. This natural alkaloid is currently in short supply and because of the large number of potential patients (c. 700,000 currently in UK) is a very expensive treatment in total for a health provider to assume. In Scotland all patients who can benefit from it, and from related drugs, have access on prescription, but in England and Wales, the National Institute for Clinical Excellence (NICE) has decided to withdraw all anti-cholinesterase treatments from the National Health Service as regards new patients, because of the high total cost of branded medicines still subject to restrictive product licence. That decision has caused an outcry from sufferers and their families, and is being disputed in the High Court. It may not be resolved until after the drugs are able to be produced and sold in generic form. Nevertheless, global demand for Galanthamine is expanding rapidly. Alzeim expects to be able to provide much-needed extra quantities of the drug at lower prices thereby enabling many more patients to benefit from this treatment. Field trials, plant species and variety screening and laboratory extraction, purification and analysis work undertaken initially in co-operation with the IGER institute of University of Wales, Aberystwyth, indicated that a feasible route existed to produce Galanthamine economically in special regimes in parts of Mid-Wales. Since then, using mechanization under agronomic conditions, Alzeim has developed new production regimes with its own cultivars.nAmong other academic collaborations Alzeim is working on aspects of Galanthamine extraction and purification with the University of Manchester.

I
IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.